AGMB - Agomab Therapeutics NV
10.85
-1.020 -9.401%
Share volume: 67,751
Last Updated: 03-27-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.04%
PREVIOUS CLOSE
CHG
CHG%
$11.87
-1.02
-0.09%
Fundamental analysis
0%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
0%
Performance
5 Days
-11.43%
1 Month
-33.07%
3 Months
-25.94%
6 Months
-25.94%
1 Year
-25.94%
2 Year
-25.94%
Key data
Stock price
$10.85
DAY RANGE
$10.51 - $12.00
52 WEEK RANGE
$10.50 - $17.45
52 WEEK CHANGE
-$25.94
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Tim Knotnerus
Region: US
Website: www.agomab.com
Employees: 62
IPO year: 2026
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Region: US
Website: www.agomab.com
Employees: 62
IPO year: 2026
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
We are a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Our principal executive offices are located in Antwerpen, Belgium.
Recent news